HC Wainwright Has Optimistic Outlook of Harrow Q2 Earnings

Harrow, Inc. (NASDAQ:HROW) – HC Wainwright upped their Q2 2026 EPS estimates for Harrow in a research note issued on Wednesday, November 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.25 for the quarter, up from their previous estimate of $0.21. HC Wainwright currently has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q3 2026 earnings at $0.29 EPS and FY2026 earnings at $1.08 EPS.

Several other research firms have also weighed in on HROW. Craig Hallum upped their price objective on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $94.00 price objective on shares of Harrow in a report on Tuesday. Lake Street Capital boosted their target price on shares of Harrow from $42.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Wednesday, October 8th. Finally, Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $71.43.

Harrow Stock Performance

HROW stock traded up $1.17 during midday trading on Thursday, hitting $39.61. The stock had a trading volume of 290,357 shares, compared to its average volume of 551,711. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. The stock has a 50-day simple moving average of $40.69 and a 200 day simple moving average of $34.87. Harrow has a 52 week low of $20.85 and a 52 week high of $50.72. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -158.42 and a beta of 0.19.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.11. The company had revenue of $71.64 million for the quarter, compared to analyst estimates of $73.70 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.

Hedge Funds Weigh In On Harrow

Several hedge funds have recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. acquired a new position in Harrow during the 1st quarter valued at about $559,000. Royce & Associates LP raised its stake in shares of Harrow by 12.0% during the first quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock worth $8,701,000 after buying an additional 35,006 shares during the last quarter. Equitable Trust Co. lifted its holdings in Harrow by 9.2% in the first quarter. Equitable Trust Co. now owns 47,570 shares of the company’s stock valued at $1,265,000 after buying an additional 4,015 shares during the period. Nuveen LLC acquired a new position in Harrow in the first quarter valued at approximately $2,046,000. Finally, HighTower Advisors LLC boosted its stake in Harrow by 30.5% in the first quarter. HighTower Advisors LLC now owns 13,217 shares of the company’s stock valued at $352,000 after acquiring an additional 3,090 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.